Drug intelligence / Profile preview

DCD-1L

Development stage
Preclinical
Modality
Antimicrobial Peptides → Native Peptides → Peptides
Administration
Intranasal
01

Overview

DCD-1L is a 48-amino acid anionic antimicrobial peptide (AMP) derived from the human protein dermcidin. It is constitutively expressed in eccrine sweat glands and secreted into sweat, where it plays a crucial role in the innate immune defense of human skin against infection. DCD-1L exhibits broad-spectrum antimicrobial activity against various pathogenic microorganisms, including Gram-positive and Gram-negative bacteria (e.g., *Staphylococcus aureus*, methicillin-resistant *S. aureus* (MRSA), *Escherichia coli*, *Enterococcus faecalis*, *Acinetobacter baumannii*) and fungi (*Candida albicans*). Its mechanism of action involves interacting with negatively charged bacterial phospholipids, forming oligomeric complexes, and subsequently creating ion channels in the bacterial membrane, leading to membrane depolarization and bacterial cell death. It is being investigated as a potential therapeutic agent for drug-resistant infections and sepsis.

Other names
Dermcidin (63-110)anionic peptide

Beyond the preview

Go deeper on DCD-1L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCD-1L.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call